23.82k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
Watchlist | Change today | 1-month return | 1-year return | Total return |
---|---|---|---|---|
The fight against COVID19 | +1.12% | - | - | - |
^GSPC | +1.17% | +5.08% | +29.15% | +5607.69% |
Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
---|---|---|---|---|---|---|---|---|
JNJ | Johnson & Johnson | 152.67 | +1.29 | +0.85% | 4:00 pm GMT-4 | 5.37M | 7.47M | 367.43B |
ABBV | AbbVie Inc. | 163.79 | +2.20 | +1.36% | 4:00 pm GMT-4 | 5.26M | 5.64M | 289.23B |
PFE | Pfizer Inc. | 28.82 | +0.44 | +1.55% | 4:01 pm GMT-4 | 34.60M | 42.78M | 163.31B |
SNY | Sanofi | 49.01 | -0.49 | -0.99% | 4:00 pm GMT-4 | 4.25M | 2.01M | 123.66B |
REGN | Regeneron Pharmaceuticals, Inc. | 978.21 | -6.43 | -0.65% | 4:00 pm GMT-4 | 590.22k | 457.32k | 107.79B |
GSK | GSK plc | 45.7 | +0.04 | +0.09% | 4:00 pm GMT-4 | 3.77M | 3.15M | 94.23B |
GILD | Gilead Sciences, Inc. | 67.01 | -0.64 | -0.95% | 4:00 pm GMT-4 | 7.53M | 7.06M | 83.48B |
MRNA | Moderna, Inc. | 129.06 | +0.74 | +0.58% | 4:00 pm GMT-4 | 2.94M | 3.85M | 49.46B |
TAK | Takeda Pharmaceutical Company Limited | 13.39 | -0.06 | -0.45% | 4:00 pm GMT-4 | 1.10M | 1.67M | 42.02B |
BNTX | BioNTech SE | 92.2 | -0.08 | -0.09% | 4:00 pm GMT-4 | 467.64k | 596.34k | 22.22B |
NVAX | Novavax, Inc. | 12.9 | -0.58 | -4.30% | 4:00 pm GMT-4 | 24.39M | 12.56M | 1.90B |
VIR | Vir Biotechnology, Inc. | 10.02 | -0.06 | -0.60% | 4:00 pm GMT-4 | 717.88k | 1.00M | 1.36B |
INO | Inovio Pharmaceuticals, Inc. | 13.07 | +1.65 | +14.45% | 4:00 pm GMT-4 | 731.54k | 445.47k | 338.60M |
Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on Thursday. The settlement was disclosed in a court filing in Delaware last week, and is aimed at reducing Pfizer's potential liability, the report added. Pfizer did not immediately reply to Reuters' request for comment.
The drugmaker was set to pay between $200 million and $250 million in the settlement, the newspaper reported, citing two people briefed on the deal. The settlement was disclosed in a court filing in Delaware last week, and is aimed at reducing Pfizer's potential liability, the report added. Pfizer did not immediately reply to Reuters' request for comment.
A potentially very lucrative arrangement with a peer doesn't necessarily make the company a buy.